Staar Surg Financials
Staar Surg (STAA) reported $239.4M in revenue for fiscal year 2025, down 23.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
STAAR Surgical's cost structure has outrun sales, leaving still-strong gross economics unable to prevent cash burn.
With gross margin essentially flat year to year, operating margin fell from-4.0% to-38.3% , showing the breakdown happened below gross profit rather than in basic product economics. That same squeeze pushed operating cash flow from$15.7M to-$34.2M , so the earnings decline was matched by a real cash drain rather than accounting noise.
Revenue fell to
Inventory rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Staar Surg's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Staar Surg has an operating margin of -38.3%, meaning the company loses $38 on every $100 of revenue. This results in a profitability score of 12/100. This is down from -4.0% the prior year.
Staar Surg's revenue declined 23.7% year-over-year, from $313.9M to $239.4M. This contraction results in a growth score of 8/100.
Staar Surg carries a low D/E ratio of 0.31, meaning only $0.31 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 68/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.55, Staar Surg holds $4.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
Staar Surg's operations used $34.2M of cash, and capex of $5.8M added to the outflow, for a free cash flow shortfall of $40.0M. This results in a cash flow score of 16/100.
Staar Surg posts a -23.4% return on equity (ROE), meaning it loses $23 for every $100 of shareholders' equity. This results in a returns score of 15/100. This is down from -5.1% the prior year.
Staar Surg scores 6.52, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($107.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Staar Surg passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Staar Surg reported a net loss of $80.4M while operations used $34.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Staar Surg generated $239.4M in revenue in fiscal year 2025. This represents a decrease of 23.7% from the prior year.
Staar Surg's EBITDA was -$83.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1396.4% from the prior year.
Staar Surg reported -$80.4M in net income in fiscal year 2025. This represents a decrease of 298.1% from the prior year.
Staar Surg earned -$1.62 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 295.1% from the prior year.
Cash & Balance Sheet
Staar Surg recorded an outflow of $40.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 422.2% from the prior year.
Staar Surg held $153.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Staar Surg's gross margin was 76.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.
Staar Surg's operating margin was -38.3% in fiscal year 2025, reflecting core business profitability. This is down 34.3 percentage points from the prior year.
Staar Surg's net profit margin was -33.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 27.2 percentage points from the prior year.
Staar Surg's ROE was -23.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.3 percentage points from the prior year.
Capital Allocation
Staar Surg invested $40.1M in research and development in fiscal year 2025. This represents a decrease of 11.6% from the prior year.
Staar Surg spent $6.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Staar Surg invested $5.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 75.1% from the prior year.
STAA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $339.6M | $239.4M-23.7% | $313.9M-2.6% | $322.4M+34.7% | $239.4M+3.9% | $230.5M+41.0% | $163.5M+8.8% | $150.2M+21.2% | $124.0M+36.8% | $90.6M+9.9% | $82.4M+6.9% | $77.1M+2.8% | $75.0M+3.8% | $72.2M+13.2% | $63.8M+1.6% | $62.8M |
| Cost of Revenue | $79.4M | $57.0M-23.3% | $74.3M+6.5% | $69.8M+14.4% | $61.0M+17.7% | $51.8M+14.9% | $45.1M+18.0% | $38.2M+17.8% | $32.4M+23.2% | $26.3M+9.4% | $24.1M-1.4% | $24.4M-6.7% | $26.2M+19.4% | $21.9M+12.4% | $19.5M-4.4% | $20.4M |
| Gross Profit | $260.2M | $182.4M-23.9% | $239.6M-5.2% | $252.7M+13.1% | $223.4M+25.0% | $178.6M+50.9% | $118.4M+5.7% | $112.0M+22.3% | $91.5M+42.4% | $64.3M+10.1% | $58.4M+10.7% | $52.7M+8.0% | $48.8M-3.0% | $50.3M+13.6% | $44.3M+4.5% | $42.4M |
| R&D Expenses | $38.3M | $40.1M-11.6% | $45.3M+12.0% | $40.5M+12.5% | $36.0M+6.3% | $33.9M+6.1% | $31.9M+26.2% | $25.3M+14.8% | $22.0M+9.9% | $20.0M-3.0% | $20.7M+40.0% | $14.8M+19.4% | $12.4M+84.3% | $6.7M+4.1% | $6.4M+9.8% | $5.9M |
| SG&A Expenses | $246.5M | $274.1M+8.7% | $252.2M+12.3% | $224.6M+25.0% | $179.6M+23.6% | $145.3M+30.2% | $111.6M+11.5% | $100.1M+17.9% | $84.9M+25.0% | $67.9M-4.4% | $71.0M+262.3% | $19.6M+7.2% | $18.3M+9.0% | $16.8M+10.7% | $15.2M+1.5% | $14.9M |
| Operating Income | $13.7M | -$91.7M-627.2% | -$12.6M-144.9% | $28.1M-35.9% | $43.8M+31.4% | $33.3M+392.5% | $6.8M-42.9% | $11.9M+79.7% | $6.6M+281.6% | -$3.6M+71.3% | -$12.7M-137.1% | -$5.3M+33.5% | -$8.0M-1246.7% | $700K+157.4% | -$1.2M-143.8% | $2.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $112K0.0% | $112K+43.6% | $78K-49.4% | $154K-9.4% | $170K-41.6% | $291K-44.4% | $523K |
| Income Tax | $13.5M | -$1.8M-116.3% | $11.2M-9.7% | $12.3M+109.8% | $5.9M+55.2% | $3.8M+61.1% | $2.4M+330.3% | -$1.0M-161.2% | $1.7M+1164.3% | -$157K+50.2% | -$315K-133.9% | $928K+466.8% | -$253K-135.3% | $716K-42.4% | $1.2M-8.3% | $1.4M |
| Net Income | $3.8M | -$80.4M-298.1% | -$20.2M-194.7% | $21.3M-46.2% | $39.7M+44.2% | $27.5M+365.3% | $5.9M-57.9% | $14.0M+182.8% | $5.0M+332.3% | -$2.1M+82.4% | -$12.1M-85.7% | -$6.5M+22.2% | -$8.4M-2208.5% | $398K+122.6% | -$1.8M-230.8% | $1.3M |
| EPS (Diluted) | — | -$1.62-295.1% | -$0.41-195.3% | $0.43-46.3% | $0.80+42.9% | $0.56+366.7% | $0.12-60.0% | $0.30+172.7% | $0.11+320.0% | -$0.05 | -$0.30-76.5% | -$0.17+22.7% | -$0.22-2300.0% | $0.01 | -$0.05-225.0% | $0.04 |
TTM is the trailing twelve months, Q3 FY2026 through Q2 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
STAA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $451.7M-11.4% | $509.5M+4.3% | $488.7M+16.7% | $418.8M+21.1% | $345.8M+34.3% | $257.4M+24.0% | $207.5M+24.0% | $167.3M+146.3% | $67.9M+3.7% | $65.5M+4.0% | $63.0M+6.9% | $58.9M-4.9% | $61.9M+13.1% | $54.8M+11.7% | $49.0M |
| Current Assets | $311.5M-15.3% | $367.9M+0.7% | $365.3M+17.2% | $311.7M+14.9% | $271.4M+25.4% | $216.4M+23.9% | $174.7M+15.2% | $151.6M+181.3% | $53.9M+8.8% | $49.5M+0.9% | $49.1M+9.3% | $44.9M-10.3% | $50.1M+13.6% | $44.1M+14.0% | $38.7M |
| Cash & Equivalents | $153.2M+6.2% | $144.2M-21.2% | $183.0M+111.7% | $86.5M-56.7% | $199.7M+31.0% | $152.5M+27.1% | $120.0M+15.5% | $103.9M+460.9% | $18.5M+32.3% | $14.0M+4.5% | $13.4M+3.0% | $13.0M-43.3% | $23.0M+5.9% | $21.7M+30.7% | $16.6M |
| Inventory | $39.7M+48.5% | $26.7M+15.4% | $23.1M+69.8% | $13.6M+30.7% | $10.4M-24.0% | $13.7M+5.7% | $13.0M-1.8% | $13.2M+18.3% | $11.2M-21.7% | $14.3M-10.4% | $15.9M+1.3% | $15.7M+25.6% | $12.5M+7.2% | $11.7M+6.8% | $10.9M |
| Accounts Receivable | $50.1M-35.7% | $77.9M-17.7% | $94.7M+51.7% | $62.4M+43.5% | $43.5M+23.6% | $35.2M+13.7% | $31.0M+19.5% | $25.9M+45.3% | $17.9M+9.2% | $16.3M+4.3% | $15.7M+41.8% | $11.1M+3.0% | $10.7M+25.6% | $8.5M-6.0% | $9.1M |
| Goodwill | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M |
| Total Liabilities | $107.5M-4.2% | $112.2M+9.2% | $102.7M+24.2% | $82.7M-5.2% | $87.2M+44.9% | $60.2M+26.4% | $47.6M+36.5% | $34.9M+39.7% | $25.0M-9.3% | $27.6M+14.4% | $24.1M+10.5% | $21.8M-5.5% | $23.1M+0.3% | $23.0M+17.7% | $19.5M |
| Current Liabilities | $68.5M-2.6% | $70.3M+8.1% | $65.0M+25.8% | $51.7M+6.0% | $48.8M+18.3% | $41.2M+19.6% | $34.5M+24.3% | $27.7M+45.3% | $19.1M-9.4% | $21.1M+17.8% | $17.9M+9.3% | $16.4M-11.1% | $18.4M+2.6% | $17.9M+28.1% | $14.0M |
| Total Equity | $344.2M-13.4% | $397.3M+2.9% | $386.0M+14.8% | $336.1M+28.5% | $261.6M+32.6% | $197.2M+23.4% | $159.9M+20.7% | $132.4M+208.4% | $42.9M+13.3% | $37.9M-2.4% | $38.8M+4.7% | $37.1M-4.5% | $38.9M+22.4% | $31.7M+7.8% | $29.5M |
| Retained Earnings | -$148.0M-119.0% | -$67.6M-42.7% | -$47.4M+31.1% | -$68.7M+36.6% | -$108.4M+20.2% | -$135.9M+4.2% | -$141.8M+9.3% | -$156.3M+3.1% | -$161.2M-1.3% | -$159.1M-8.3% | -$147.0M-4.7% | -$140.4M-6.4% | -$132.1M+0.3% | -$132.5M-1.3% | -$130.7M |
Not reported in any period shown, so not listed: Long-Term Debt.
STAA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M | -$34.2M-317.7% | $15.7M+7.7% | $14.6M-59.1% | $35.7M-18.8% | $44.0M+109.8% | $21.0M-18.8% | $25.8M+102.0% | $12.8M+347.5% | $2.9M+172.0% | $1.0M+148.5% | -$2.2M+72.8% | -$8.0M-337.0% | $3.4M+4.3% | $3.2M-39.8% | $5.3M |
| Capital Expenditures | $3.5M | $5.8M-75.1% | $23.4M+28.6% | $18.2M+0.4% | $18.1M+32.7% | $13.6M+62.4% | $8.4M-16.8% | $10.1M+349.7% | $2.2M+114.6% | $1.0M-67.4% | $3.2M+56.7% | $2.0M-49.6% | $4.1M+17.6% | $3.4M+51.8% | $2.3M+136.1% | $962K |
| Free Cash Flow | -$6.7M | -$40.0M-422.2% | -$7.7M-113.4% | -$3.6M-120.4% | $17.6M-41.9% | $30.3M+141.6% | $12.5M-20.1% | $15.7M+49.2% | $10.5M+482.3% | $1.8M+183.8% | -$2.2M+48.8% | -$4.2M+65.0% | -$12.0M-12808.6% | -$93K-109.8% | $946K-78.4% | $4.4M |
| Investing Cash Flow | -$13.4M | $46.3M+178.3% | -$59.2M-179.6% | $74.3M+147.5% | -$156.4M-1046.0% | -$13.6M-62.4% | -$8.4M+17.4% | -$10.2M-353.4% | -$2.2M-114.6% | -$1.0M+67.4% | -$3.2M-56.9% | -$2.0M | N/A | N/A | -$2.1M-141.4% | -$889K |
| Financing Cash Flow | -$2.3M | -$4.6M-179.6% | $5.7M-22.8% | $7.4M-10.6% | $8.3M-53.4% | $17.8M-9.1% | $19.6M+13034.9% | $149K-99.8% | $74.6M+2962.7% | $2.4M-17.5% | $3.0M-35.5% | $4.6M | N/A | N/A | $4.3M+54.7% | $2.8M |
| Share Buybacks | N/A | $6.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2026 through Q2 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
STAA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.2%-0.1pp | 76.3%-2.0pp | 78.4%-14.9pp | 93.3%+15.8pp | 77.5%+5.1pp | 72.4%-2.1pp | 74.5%+0.7pp | 73.8%+2.9pp | 70.9%+0.1pp | 70.8%+2.4pp | 68.4%+3.2pp | 65.1%-4.6pp | 69.7%+0.2pp | 69.4%+1.9pp | 67.5% |
| Operating Margin | -38.3%-34.3pp | -4.0%-12.7pp | 8.7%-9.6pp | 18.3%+3.8pp | 14.5%+10.3pp | 4.1%-3.8pp | 7.9%+2.6pp | 5.3%+9.3pp | -4.0%+11.3pp | -15.3%-8.4pp | -6.9%+3.8pp | -10.7%-11.7pp | 1.0%+2.9pp | -1.9%-6.3pp | 4.4% |
| Net Margin | -33.6%-27.2pp | -6.4%-13.1pp | 6.6%-9.9pp | 16.6%+4.6pp | 11.9%+8.3pp | 3.6%-5.7pp | 9.3%+5.3pp | 4.0%+6.4pp | -2.4%+12.4pp | -14.7%-6.2pp | -8.5%+2.7pp | -11.2%-11.7pp | 0.5%+3.3pp | -2.8%-4.9pp | 2.1% |
| Return on Equity | -23.4%-18.3pp | -5.1%-10.6pp | 5.5%-6.3pp | 11.8%+1.3pp | 10.5%+7.5pp | 3.0%-5.8pp | 8.8%+5.0pp | 3.8%+8.7pp | -5.0%+27.0pp | -32.0%-15.2pp | -16.8%+5.8pp | -22.6%-23.6pp | 1.0%+6.6pp | -5.5%-10.1pp | 4.6% |
| Return on Assets | -17.8%-13.8pp | -4.0%-8.3pp | 4.4%-5.1pp | 9.5%+1.5pp | 8.0%+5.7pp | 2.3%-4.5pp | 6.8%+3.8pp | 3.0%+6.1pp | -3.1%+15.4pp | -18.5%-8.1pp | -10.4%+3.9pp | -14.2%-14.9pp | 0.6%+3.9pp | -3.2%-6.0pp | 2.8% |
| Current Ratio | 4.55-0.7x | 5.23-0.4x | 5.62-0.4x | 6.03+0.5x | 5.56+0.3x | 5.25+0.2x | 5.07-0.4x | 5.47+2.6x | 2.82+0.5x | 2.35-0.4x | 2.740.0x | 2.740.0x | 2.72+0.3x | 2.46-0.3x | 2.76 |
| Debt-to-Equity | 0.310.0x | 0.280.0x | 0.270.0x | 0.25-0.1x | 0.330.0x | 0.310.0x | 0.300.0x | 0.26-0.3x | 0.58-0.1x | 0.73+0.1x | 0.620.0x | 0.590.0x | 0.59-0.1x | 0.73+0.1x | 0.66 |
| FCF Margin | -16.7%-14.3pp | -2.4%-1.3pp | -1.1%-8.5pp | 7.3%-5.8pp | 13.2%+5.5pp | 7.7%-2.8pp | 10.4%+2.0pp | 8.5%+6.5pp | 2.0%+4.6pp | -2.6%+2.8pp | -5.5%+10.6pp | -16.0%-15.9pp | -0.1%-1.6pp | 1.5%-5.5pp | 7.0% |
Similar Companies
Where Staar Surg Ranks
Frequently Asked Questions
What is Staar Surg's annual revenue?
Staar Surg (STAA) reported $239.4M in total revenue for fiscal year 2025. This represents a -23.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Staar Surg's revenue growing?
Staar Surg (STAA) revenue declined by 23.7% year-over-year, from $313.9M to $239.4M in fiscal year 2025.
Is Staar Surg profitable?
No, Staar Surg (STAA) reported a net income of -$80.4M in fiscal year 2025, with a net profit margin of -33.6%.
What is Staar Surg's EBITDA?
Staar Surg (STAA) had EBITDA of -$83.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Staar Surg's gross margin?
Staar Surg (STAA) had a gross margin of 76.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Staar Surg's operating margin?
Staar Surg (STAA) had an operating margin of -38.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Staar Surg's net profit margin?
Staar Surg (STAA) had a net profit margin of -33.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Staar Surg's return on equity (ROE)?
Staar Surg (STAA) has a return on equity of -23.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Staar Surg's free cash flow?
Staar Surg (STAA) recorded an outflow of $40.0M in free cash flow during fiscal year 2025. This represents a -422.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Staar Surg's operating cash flow?
Staar Surg (STAA) recorded an outflow of $34.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Staar Surg's total assets?
Staar Surg (STAA) had $451.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Staar Surg's capital expenditures?
Staar Surg (STAA) invested $5.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Staar Surg spend on research and development?
Staar Surg (STAA) invested $40.1M in research and development during fiscal year 2025.
What is Staar Surg's current ratio?
Staar Surg (STAA) had a current ratio of 4.55 as of fiscal year 2025, which is generally considered healthy.
What is Staar Surg's debt-to-equity ratio?
Staar Surg (STAA) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Staar Surg's return on assets (ROA)?
Staar Surg (STAA) had a return on assets of -17.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Staar Surg's cash runway?
Based on fiscal year 2025 data, Staar Surg (STAA) had $153.2M in cash against an annual operating cash burn of $34.2M. This gives an estimated cash runway of approximately 54 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Staar Surg's Altman Z-Score?
Staar Surg (STAA) has an Altman Z-Score of 6.52, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Staar Surg's Piotroski F-Score?
Staar Surg (STAA) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Staar Surg's earnings high quality?
Staar Surg (STAA) reported a net loss of $80.4M while operations used $34.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Staar Surg?
Staar Surg (STAA) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.